
Tetra Bio-Pharma Inc. (OTCQB:TBPMF) (TSX:TBP) (FRA:JAM1) has entered into a research and development agreement with Cannvalate Pty Ltd for the initiation of the REBORN, PLENITUDE and CAUMZ clinical trials in Australia, and a subscription agreement contemplating a private placement of common shares in the capital of the company with Cannvalate for aggregate proceeds to the company of up to CA$7.5 million ($5.86 million).
The company has also appointed Dr. Sud Agarwal as a special advisor to the CEO and the board of directors with a mandate to advise on strategic aspects of the company's activities and to aid in the advancement of our key programs: QIXLEEF and CAUMZ.